Introduction {#S0001}
============

Testicular germ cell tumors (TGCT) are rare tumors in the general population but are the most commonly occurring malignancy among males between ages 15 and 44 years.[@CIT0001] Radical orchidectomy is the standard treatment method.[@CIT0002],[@CIT0003] Recently, immunotherapy and gene therapy are suggested to be potential therapeutic strategies.[@CIT0004]--[@CIT0006] Understanding the molecular mechanism of tumorigenesis is important for a better clinical application of the novel treatments, as well as early diagnosis of disease and prognostic prediction. In the present study, we aim to identify key genes associated with the tumorigenesis of seminoma, based on the data from the Gene Expression Omnibus (GEO) database, for a better knowledge about the mechanism at the genetic level and exploring potential candidate genes or molecules for diagnosis, treatment, and prognosis.

Materials and methods {#S0002}
=====================

Microarray data {#S0002-S2001}
---------------

The gene expression profile (GSE8607), containing 40 seminoma samples and three healthy testes samples, was downloaded from the GEO database. GSE8607, which was submitted by Gashaw, was based on the Affymetrix GPL8300 platform (\[HG_U95Av2Affymetrix\] Human Genome U95 Version 2 Array). The average age of the 40 patients with seminoma was 37.6 (23--56) years old, while 53 years old in the control group. The American Joint Committee on Cancer (AJCC) stage distribution of these seminoma samples is as follows: 35 with stage I, 3 with stage II, and 2 with stage III.

Identification of DEGs {#S0002-S2002}
----------------------

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) is a free online tool for comparing several groups of gene expression data in a GEO Series.[@CIT0007] We applied it to detect the differentially expressed genes (DEGs) between seminoma samples and normal testes samples. Adjust *P*-value\<0.05 was thought significant statistically and \|logFC\| ≥2 was set as the cut-off criterion for a better accuracy and significance as described earlier.[@CIT0008],[@CIT0009]

GO and KEGG pathway analysis {#S0002-S2003}
----------------------------

Gene ontology (GO) analysis is a useful method for functional studies of high-throughput genomes or transcriptome data,[@CIT0010],[@CIT0011] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis is employed for the systematic analysis of gene functions by linking genomic information with higher-order functional information.[@CIT0012] To visualize core biological processes (BP), molecular functions (MF), and cellular component (CC) pathways among the DEGs, we used Functional Annotation Tool of Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 (<https://david.ncifcrf.gov/>).[@CIT0013] Adjust *P*-value\<0.05 was considered statistically significant.

Hub genes selection and analysis of modules from PPI networks {#S0002-S2004}
-------------------------------------------------------------

Search Tool for the Retrieval of Interacting Genes (STRING) is a biological database for building protein--protein interaction (PPI) networks, providing a system-wide view of interactions between each member.[@CIT0014] DEGs were mapped to STRING to analyze their relationships with each other, and a combined score of \>0.4 was set as the cut-off criterion described before. PPI networks were then established using Cytoscape software,[@CIT0015] which visually explores biomolecular interaction networks composed of proteins, genes, and other molecules. The plug-in Centiscape was used to search for the most important nodes in a network by calculating centrality parameters for each node.[@CIT0015] Hub genes were selected from the PPI network according to the degree of connectivity. The plug-in Molecular Complex Detection (MCODE) was used to select modules from the PPI network with the criteria as described before: node score cutoff=0.2, degree cutoff=2, max depth=100, and k-core=2.[@CIT0009] Pathway analyses of genes in each module were performed using DAVID, with adjust *P*-value\<0.05 considered statistically significant.

Comparison of the hub genes expression level {#S0002-S2005}
--------------------------------------------

GEPIA (<http://gepia.cancer-pku.cn/index.html>) is a web server for cancer and normal gene expression profiling and interactive analyses, based on the data from TCGA and the GTEx project.[@CIT0016] We used it to validate the different expression levels of the hub genes between seminoma tissues and normal testes tissues. Then, the box plot was performed to visualize the relationship.

Survival analyses of hub genes {#S0002-S2006}
------------------------------

The expression profiles of 134 seminoma samples, along with the clinical data were downloaded from the TCGA database (<http://tcga-data.nci.nih.gov>) for survival analyses of hub genes. The hazard ratio (HR) with 95% confidence intervals and log-rank *P*-value were calculated and displayed. Log-rank *P*-value\<0.05 was considered statistically significant.

Results {#S0003}
=======

Identification of DEGs {#S0003-S2001}
----------------------

The study included 40 seminoma samples and three healthy testes samples. A total of 1,636 DEGs were selected after the analysis of GSE8607 by GEO2R. Of these, 701 were up-regulated and 935 were down-regulated in seminoma samples compared with healthy controls. A volcano plot and heat map of DEGs are shown in [Figure 1A](#F0001){ref-type="fig"} and B, respectively.Figure 1Selection of DEGs and function annotation. (**A**) Volcano plot of the DEGs (adjust *P*-value \<0.05 and \|logFC\| ≥2 were set as the cut-off criteria). (**B**) Heat map of the top 100 DEGs (top 50 up-regulated and down-regulated genes). (**C**) Genes ontology analysis of up-regulated DEGs. (**D**) Genes ontology analysis of down-regulated DEGs. (**E)** KEGG pathway analysis of DEGs.

GO term and KEGG pathway analyses {#S0003-S2002}
---------------------------------

For a deeper insight into the DEGs, we performed GO and KEGG pathway enrichment analyses. GO BP analysis revealed that up-regulated DEGs were mainly involved in the regulation of immune system processes and defense responses; while down-regulated DEGs were mainly associated with reproductive processes. GO MF analysis showed that the up-regulated DEGs were mainly enriched in receptor binding, signal transducer activity, receptor activity, molecular transducer activity, and protein complex binding; while down-regulated DEGs were significantly enriched in kinase activity, carbohydrate derivative binding, protein serine/threonine kinase activity, adenyl nucleotide binding, and adenyl ribonucleotide binding. GO CC analysis showed that up-regulated DEGs were involved with intrinsic components of plasma membranes, cell surface, side of membranes, integral components of plasma membranes, and external side of plasma membranes; while down-regulated DEGs were mainly associated with cilium and neuron projections. GO analysis findings are shown in [Figure 1C](#F0001){ref-type="fig"} and D, and [Table 1](#T0001){ref-type="table"}.Table 1Gene ontology analysis of DEGs associated with seminomaExpressionCategoryTermCount%*P*-valueFDRUp-regulatedGOTERM_BP_FATImmune response20636.206.12E−761.19E−72GOTERM_BP_FATRegulation of immune system process16629.174.71E−539.19E−50GOTERM_BP_FATDefense response16829.531.39E−482.71E−45GOTERM_BP_FATPositive regulation of immune system process13022.854.61E−469.00E−43GOTERM_BP_FATRegulation of immune response12622.141.75E−453.41E−42GOTERM_MF_FATReceptor binding11219.681.01E−171.62E−14GOTERM_MF_FATSignal transducer activity11319.862.74E−124.42E−09GOTERM_MF_FATReceptor activity10418.282.08E−103.36E−07GOTERM_MF_FATMolecular transducer activity10418.282.08E−103.36E−07GOTERM_MF_FATProtein complex binding6110.723.30E−105.33E−07GOTERM_CC_FATIntrinsic component of plasma membrane13223.201.36E−192.02E−16GOTERM_CC_FATCell surface8114.242.44E−193.60E−16GOTERM_CC_FATSide of membrane6010.542.75E−194.06E−16GOTERM_CC_FATIntegral component of plasma membrane12822.502.89E−194.27E−16GOTERM_CC_FATExternal side of plasma membrane447.738.94E−191.32E−15Down-regulatedGOTERM_BP_FATReproductive process14519.039.16E−271.79E−23GOTERM_BP_FATReproduction14519.031.06E−262.08E−23GOTERM_BP_FATSingle organism reproductive process13317.452.37E−254.63E−22GOTERM_BP_FATSexual reproduction9812.861.32E−232.58E−20GOTERM_BP_FATMulti-organism reproductive process10714.044.11E−228.04E−19GOTERM_MF_FATKinase activity749.716.64E−081.08E−04GOTERM_MF_FATCarbohydrate derivative binding14118.502.01E−073.27E−04GOTERM_MF_FATProtein serine/threonine kinase activity435.649.12E−071.49E−03GOTERM_MF_FATAdenyl nucleotide binding10313.521.06E−061.72E−03GOTERM_MF_FATAdenyl ribonucleotide binding10213.391.35E−062.20E−03GOTERM_CC_FATCilium557.221.78E−092.70E−06GOTERM_CC_FATNeuron projection759.841.04E−061.58E−03GOTERM_CC_FATCiliary part374.861.40E−062.12E−03GOTERM_CC_FATCytosol19625.725.46E−068.26E−03GOTERM_CC_FATNeuron part9212.077.43E−061.12E−02

[Table 2](#T0002){ref-type="table"} and [Figure 1E](#F0001){ref-type="fig"} show the results of KEGG analysis. Up-regulated DEGs were mainly enriched in cytokine--cytokine receptor interactions, cell adhesion molecules (CAMs), phagosomes, osteoclast differentiation, leukocyte transendothelial migration, natural killer cell-mediated cytotoxicity, chemokine signaling pathways, and antigen processing and presentation; down-regulated DEGs were significantly enriched in tight junctions, pyruvate metabolism, the cell cycle, glutamatergic synapses, metabolic pathways, ovarian steroidogenesis, axon guidance, and calcium signaling pathways.Table 2KEGG pathway analysis of DEGs associated with seminomaExpressionPathway IDTermCount%*P*-valueFDRGenesUp-regulatedhsa04060Cytokine−cytokine receptor interaction447.735.35E−156.77E-12*IL1R2*, *CCL3*, *CCL2*, *PDGFB*, *TNFRSF25*, *CCR1*, *CXCL9*, *FASLG*, *CCL8*, *KIT*, *CCL5*, *CXCL11*, *CCL4*, *TNFRSF4*, *IL10*, *FLT3LG*, *CXCL10*, *TNFRSF1B*, *TNFRSF11B*, *IL23A*, *CXCR5*, *CXCR4*, *IFNA5*, *IL10RA*, *CXCR6*, *IFNG*, *CSF2RB*, *IL1B*, *IL2RG*, *LTB*, *CSF2RA*, *CD27*, *IL6*, *IL2RB*, *CCL19*, *IL6R*, *IFNAR2*, *CCR8*, *TNFSF10*, *CCR5*, *CXCL13*, *CCR2*, *VEGFA*, *ACVR1*hsa04514Cell adhesion molecules (CAMs)274.752.78E−093.54E−06*ITGAL*, *CLDN7*, *CD8A*, *CDH1*, *L1CAM*, *ITGB2*, *HLA-DMB*, *CDH3*, *HLA-DMA*, *ITGAM*, *NRCAM*, *CD2*, *HLA-DRB4*, *CD4*, *HLA-DPB1*, *HLA-DOA*, *CD28*, *ICAM1*, *PTPRC*, *SELL*, *ICAM2*, *ITGA4*, *HLA-E*, *HLA-F*, *PECAM1*, *HLA-DPA1*, *HLA-DRA*hsa04145Phagosome284.923.17E−094.03E−06*TUBB2B*, *TLR2*, *ITGB2*, *HLA-DMB*, *ATP6V1B1*, *HLA-DMA*, *ITGAM*, *TUBB*, *TAP2*, *HLA-DRB4*, *HLA-DPB1*, *FCGR3A*, *THBS1*, *HLA-DOA*, *FCGR3B*, *NCF2*, *NCF4*, *CTSS*, *HLA-E*, *HLA-F*, *CYBA*, *CORO1A*, *CYBB*, *ITGA5*, *HLA-DPA1*, *FCGR2A*, *CD14*, *HLA-DRA*hsa04380Osteoclast differentiation254.391.15E−081.46E−05*NCF2*, *NCF4*, *ACP5*, *NFKB2*, *STAT1*, *JUNB*, *BTK*, *STAT2*, *LILRB1*, *IRF9*, *IFNAR2*, *LILRB2*, *CYBA*, *TNFRSF11B*, *CYBB*, *LILRB3*, *LCK*, *IFNG*, *LILRB4*, *IL1B*, *FCGR2A*, *FCGR3A*, *FCGR3B*, *TYROBP*, *LCP2*hsa04670Leukocyte transendothelial migration223.871.63E−072.07E−04*ICAM1*, *ITGAL*, *CLDN7*, *MYL7*, *ITK*, *NCF2*, *MMP9*, *NCF4*, *SIPA1*, *ACTN1*, *ITGB2*, *ITGA4*, *ITGAM*, *VASP*, *THY1*, *CYBA*, *CYBB*, *RAC2*, *CXCR4*, *PECAM1*, *MSN*, *RHOH*hsa04650Natural killer cell mediated cytotoxicity223.872.94E−073.73E−04*ICAM1*, *ITGAL*, *PTPN6*, *ICAM2*, *CD247*, *FASLG*, *ITGB2*, *GZMB*, *NCR1*, *CD48*, *IFNAR2*, *TNFSF10*, *SH2D1A*, *RAC2*, *IFNA5*, *LCK*, *IFNG*, *FCER1G*, *FCGR3A*, *FCGR3B*, *TYROBP*, *LCP2*hsa04062Chemokine signaling pathway274.758.07E−071.03E−03*CCL3*, *CCL2*, *CCR1*, *CXCL9*, *CCL8*, *CXCL11*, *CCL5*, *CCL4*, *CXCL10*, *RAC2*, *CXCR5*, *CXCR4*, *CXCR6*, *ITK*, *LYN*, *HCK*, *CCL19*, *STAT1*, *CCL18*, *STAT2*, *CCR8*, *CCR5*, *ARRB2*, *CXCL13*, *CCR2*, *GRK5*, *XCL2*hsa04612Antigen processing and presentation162.812.59E−063.29E−03*CD8A*, *CTSS*, *HLA-DMB*, *HLA-E*, *HLA-DMA*, *CD74*, *HLA-F*, *B2M*, *TAP2*, *IFNG*, *HLA-DRB4*, *CD4*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DOA*, *HLA-DRA*Down-regulatedhsa04530Tight junction172.235.54E−047.16E−01*PPP2R1B*, *PRKCZ*, *CLDN18*, *MYL5*, *MAGI1*, *GNAI1*, *MYH3*, *MYLPF*, *MYH7*, *ACTN3*, *CTNNA2*, *CSNK2A2*, *EPB41L3*, *MYH11*, *EXOC3*, *TJP3*, *TJP2*hsa00620Pyruvate metabolism81.052.13E−032.73E+00*HAGH*, *LDHC*, *ME1*, *ME3*, *ACYP1*, *PDHA2*, *ACACB*, *PC*hsa04110Cell cycle141.844.68E−035.90E+00*CCNE2*, *CDKN1C*, *E2F2*, *FZR1*, *CDKN1B*, *RBL2*, *CDKN2B*, *CCNH*, *DBF4*, *CDKN2D*, *CDK6*, *PTTG1*, *CDC25C*, *CCNA1*hsa04724Glutamatergic synapse121.571.61E−021.90E+01*PRKACG*, *SLC1A2*, *DLGAP1*, *GNAO1*, *GRIA2*, *ADCY9*, *GNAI1*, *GRM8*, *SLC1A6*, *PPP3CC*, *CACNA1C*, *GRK3*hsa01100Metabolic pathways729.452.27E−022.58E+01*LDHC*, *KYNU*, *CYP2J2*, *PGAM2*, *ITPKA*, *CKB*, *AKR1C3*, *TYR*, *AKR1C4*, *AGPS*, *PTGES*, *RGN*, *PDHA2*, *PCYT2*, *NT5E*, *NMNAT2*, *DDC*, *ALDH6A1*, *HYAL3*, *PDXK*, *GATM*, *CYP11A1*, *PFKP*, *CDS1*, *GMPS*, *NME5*, *ALOX15*, *ADO*, *PTGDS*, *CHPF*, *RFK*, *ABAT*, *PLA2G6*, *INPP4B*, *INPP1*, *GALNT3*, *ME1*, *CHKA*, *ME3*, *MVD*, *GK2*, *HMGCS1*, *HPRT1*, *ALDH1A1*, *TYMS*, *CKMT2*, *PLCH1*, *HSD17B3*, *PLCD1*, *PCYT1B*, *PRPS1L1*, *UGT8*, *MTMR6*, *SPAM1*, *GAD1*, *ODC1*, *PLA2G16*, *UAP1*, *SPHK2*, *MAOA*, *BCKDHB*, *MGAT4C*, *SI*, *ACACB*, *GAPDHS*, *CYP17A1*, *ACSM1*, *PYGM*, *HMGCS2*, *GAMT*, *PC*, *LIPF*hsa04913Ovarian steroidogenesis70.922.46E−022.76E+01AKR1C3, PRKACG, CYP17A1, CYP2J2, ADCY9, CYP11A1, STARhsa04360Axon guidance121.573.29E−023.52E+01*EPHA5*, *DCC*, *EPHA4*, *PAK3*, *GNAI1*, *ROBO1*, *EFNB2*, *SEMA3D*, *SRGAP3*, *PPP3CC*, *SEMA3C*, *EPHB1*hsa04020Calcium signaling pathway151.973.76E−023.92E+01SPHK2*EPHB1* *ERBB4*, *SLC25A4*, *PHKG2*, *ITPKA*, *PRKACG*, *CAMK4*, *ADCY9*, *PLN*, *PDE1A*, *PPP3CC*, *PLCD1*, *CACNA1C*, *MYLK*, *HTR2A*

Identification of hub genes and analysis of modules from PPI networks {#S0003-S2003}
---------------------------------------------------------------------

According to the information from STRING, the top five hub nodes were selected, including interleukin 6 (*IL6*), vascular endothelial growth factor A (*VEGFA*), including interleukin 10 (*IL10*), C-C motif chemokine receptor 5 (*CCR5*), and C-X-C motif chemokine receptor 4 (*CXCR4*). Analysis of the relationship between 1,074 nodes and 4,633 edges by plug-in MCODE enabled four modules to be selected, and then functional annotation of the genes from these modules was conducted by DAVID ([Figure 2](#F0002){ref-type="fig"}, [Tables 3](#T0003){ref-type="table"}--[6](#T0006){ref-type="table"}). The genes in these modules were mainly involved in the Janus kinase-signal transducers and activators of transcription (Jak--STAT) signaling pathway, chemokine signaling pathway, endocytosis, and cytokine--cytokine receptor interactions.Table 3The enriched pathways of module 1Term*P*-valueFDRGenesChemokine signaling pathway4.19E−174.35E−14*GNAI1*, *CCR1*, *CXCL9*, *CCL19*, *CXCL11*, *CCL5*, *CXCL10*, *CCR8*, *CXCR5*, *ADCY9*, *CCR5*, *CXCR4*, *CXCL13*, *CCR2*, *CXCR6*Cytokine−cytokine receptor interaction1.36E−121.41E−09*CCR1*, *CXCL9*, *CCL19*, *CXCL11*, *CCL5*, *CXCL10*, *CCR8*, *CCR5*, *CXCR5*, *CXCL13*, *CXCR4*, *CCR2*, *CXCR6*Neuroactive ligand-receptor interaction2.23E−042.31E−01*OPRM1*, *GRM8*, *P2RY14*, *FPR3*, *HTR1D*, *ADORA1*, *NPY5R*Toll-like receptor signaling pathway4.97E−035.04E+00*CXCL9*, *CCL5*, *CXCL11*, *CXCL10*Regulation of lipolysis in adipocytes1.46E−021.42E+01*ADCY9*, *GNAI1*, *ADORA1* Table 4The enriched pathways of module 2Term*P*-valueFDRGenesEndocytosis8.30E−078.76E−04*SH3GL3*, *ADRB2*, *ARRB2*, *CBL*, *DNAJC6*, *GRK5*, *HLA-E*, *BIN1*, *CLTCL1*, *SH3GL2*, *HLA-F*Antigen processing and presentation3.03E−063.19E−03*CD4*, *HLA-DPA1*, *HLA-DPB1*, *HLA-E*, *HLA-DRA*, *HLA-F*, *B2M*Cell adhesion molecules (CAMs)1.09E−041.15E−01*ICAM1*, *CD4*, *HLA-DPA1*, *HLA-DPB1*, *HLA-E*, *HLA-DRA*, *HLA-F*Neuroactive ligand-receptor interaction6.68E−047.03E−01*P2RY6*, *P2RY10*, *ADRB2*, *AVPR1B*, *F2RL1*, *NMBR*, *PTAFR*, *HTR2A*Phagosome9.50E−039.58E+00*HLA-DPA1*, *HLA-DPB1*, *HLA-E*, *HLA-DRA*, *HLA-F* Table 5The enriched pathways of module 3Term*P*-valueFDRGenesCytokine−cytokine receptor interaction3.34E−053.56E−02*IL5*, *CCL2*, *PDGFB*, *VEGFA*, *IFNG*, *IL1B*, *CCL4*Phagosome8.49E−049.01E−01*TLR2*, *THBS1*, *FCGR3A*, *FCGR3B*, *ITGAM*Osteoclast differentiation6.00E−036.21E+00*IFNG*, *IL1B*, *FCGR3A*, *FCGR3B*Complement and coagulation cascades1.66E−021.64E+01*FGA*, *SERPING1*, *SERPINA1*Rap1 signaling pathway2.15E−022.07E+01*PDGFB*, *VEGFA*, *THBS1*, *ITGAM* Table 6The enriched pathways of module 4Term*P*-valueFDRGenesJak-STAT signaling pathway9.16E−089.76E−05*IL6*, *IL23A*, *CCND2*, *IL7*, *CSF2RB*, *IL13*, *IL2RG*, *IL10*, *CSF2RA*Cytokine-cytokine receptor interaction2.40E−072.56E−04*IL6*, *CCL3*, *IL23A*, *IL7*, *CSF2RB*, *IL13*, *IL2RG*, *IL10*, *CSF2RA*, *ACVR1*Cell cycle1.66E−031.75E+00*FZR1*, *CCND2*, *CCNH*, *CDK6*, *CDK4*Ubiquitin mediated proteolysis2.39E−032.52E+00*FZR1*, *NEDD4*, *SMURF1*, *PARK2*, *UBE2H*PI3K-Akt signaling pathway1.33E−021.33E+01*IL6*, *CCND2*, *IL7*, *IL2RG*, *CDK6*, *CDK4* Figure 2Top four modules from the PPI network. (**A**) modules 1; (**B**) modules 2; (**C**) modules 3; (**D**) modules 4.

Expression level and survival analysis of hub genes {#S0003-S2004}
---------------------------------------------------

Compared with the normal tissues, *CCR5* and *CXCR4* revealed higher expression levels in seminoma tissues (*P*\<0.05), but *IL6, VEGFA* and *IL10* not ([Figure 3A](#F0003){ref-type="fig"}--E). Besides, 134 seminoma samples from TCGA database, grouped by the different expression of *CCR5* and *CXCR4*, were used to conduct survival analyses. [Table 7](#T0007){ref-type="table"} shows the clinicopathological characteristics in patients with seminoma from TCGA cohort. It was found that increased expression level of *CCR5* (HR 0.72 \[0.52--0.98\], *P*=0.047) was associated with poor overall survival for seminoma patients, as well as *CXCR4* (HR 0.73 \[0.59--0.92\], *P*=0.012) ([Figure 3F](#F0003){ref-type="fig"} and G).Table 7The clinicopathological characteristics in patients with seminoma from TCGA cohortExpression of CCR5*P*-valueExpression of CXCR4*P*-valueLow (n=107)High (n=27)Low (n=47)High (n=87)Age0.3050.239\<40 y88254271≥40 y192516Race0.4420.133White95234574Yellow7117Black5316AJCC stage0.2880.588I76233368II14279III172710Survival0.3800.297Yes105254783No2204[^2] Figure 3Expression levels and survival analyses of DEGs. (**A--E**) Expression levels of the five hub genes. \**P*-value \<0.05. (**F--G**) Kaplan-Meier plot of overall survival for *CCR5* and *CXCR4* in seminoma patients.**Abbreviation:** HR, hazard ratio.

Discussion {#S0004}
==========

Seminoma accounts for the most part of cases of TGCT, which is the most common malignancy among males between ages 15 and 44 years.[@CIT0001] Understanding its molecular mechanism in genetic aspects is important for diagnosis and treatment. In the present study, we analyzed the gene expression profile GSE8607, containing 40 seminoma samples and three healthy testes samples, by bioinformatics methods, to explore the hub genes which may play crucial roles in tumorigenesis. We identified 1,636 DEGs, of which 701 were up-regulated and 935 were down-regulated in seminomas compared with control testes.

GO analysis showed that up-regulated DEGs were mainly enriched in defense responses, receptor activity, regulation of immune response processes, and signal transducer activity, while down-regulated DEGs were mainly enriched in reproductive processes, kinase activity, and carbohydrate derivative binding. Regarding KEGG pathway enrichment analysis, up-regulated DEGs were enriched in CAMs, natural killer cell-mediated cytotoxicity, cytokine--cytokine receptor interactions, and chemokine signaling pathways. Previous studies have suggested that cell adhesion plays an important part in the growth, progression, and metastasis of tumors. Moreover, high expression level of CAMs was reported to be associated with poor prognosis in lung and breast cancer, and many other tumor types.[@CIT0017]--[@CIT0019] In recent years, natural killer T cells were found to be an effective treatment for several cancers, but their efficacy in seminoma remains unknown.[@CIT0020]

We showed that down-regulated DEGs were mainly associated with tight junctions, metabolic pathways, axon guidance, the cell cycle, and calcium signaling pathways. Tight junctions of healthy testes separate the internal and external environment of the testis and protect it from harmful substances. However, it is difficult to maintain a normal structure and function in cancer tissue. Moreover, studies have suggested that the loss of cell cycle regulation leads to genomic instability, and the cell cycle is thought to play an important role in the etiology of spontaneous cancers.[@CIT0021] Recent evidence indicated that physiological calcium signaling regulated aerobic metabolism, but that pathological calcium overload contributed to cell death.[@CIT0022] Therefore, monitoring these processes and pathways may aid the diagnosis or treatment of seminoma.

*IL6, VEGFA, IL10, CCR5*, and *CXCR4* were selected as hub genes because of their high degree of connectivity. Existing evidence suggests that immunologic factors may affect the development of seminoma, with the inflammatory cytokines IL6 and IL10 thought to promote tumor immune evasion through local immunosuppression. Parker et al reported that the extent of lymphocyte infiltration in seminomas was associated with a reduced risk of disease recurrence,[@CIT0023] while Klein et al documented major roles for IL6 in shaping the surrounding tumor microenvironment by influencing local immune responses.[@CIT0024] *IL6* may, therefore, have the potential to become a novel diagnostic and immunotherapeutic factor for seminoma.[@CIT0025] However, details about signaling and intercellular interaction require further investigation. Mohamed reported that IL10 secreted by tumor-infiltrating monocytes/macrophages (CD14+/CD16+) separated from inflammatory breast cancer patients positively correlated with the expression level of *CPB2*, which was crucial to lymphovascular invasion in inflammatory breast cancer.[@CIT0026] However, further studies are required to clarify the role of IL10 in seminoma.

Angiogenesis is crucial to the progression of many kinds of tumors because of the need for nutrition from blood vessels.[@CIT0027] VEGFA is a subtype of VEGF that functions as a potent angiogenic factor in blood vessel formation and regulates the progression of tumors.[@CIT0028],[@CIT0029] VEGFA promotes tumor proliferation and angiogenesis by activating phosphoinositide 3-kinase (PI3K)/AKT and extracellular-signal-regulated kinase (ERK) signaling pathways.[@CIT0030]--[@CIT0032] Although anti-angiogenesis therapies targeting *VEGFA* inhibit the progression of many tumor types, their efficacy in seminoma needs to be investigated. The gene *CCR5*, encoding one of the receptors of C-C chemokine ligand 5 (*CCL5*), promotes carcinogenesis, stroma genesis, and tumor progression.[@CIT0033] *CCL5*/*CCR5* operates via PI3K/AKT, mitogen-activated protein kinase kinase, and ERK, which in turn activate nuclear factor-κB, leading to activation of αvβ3 integrin and contributing to cell migration.[@CIT0034]--[@CIT0036] *CCL5*/*CCR5* was found to be a biomarker of poor prognosis in various cancer types such as pancreas, prostate, breast, ovarian, and renal cancers.[@CIT0037]--[@CIT0041] CXCR4 is one of the most commonly overexpressed cytokine receptors in malignant tumors, and it accepts the signal of its ligand CXCL12 to mediate cell adhesion, angiogenesis, proliferation, metastasis, and survival.[@CIT0042] Both CXCR4 and CXCL12 are important components of the signaling mechanisms that facilitate the normal migration of primordial germ cells from the hindgut to the genital ridges in fish and mammals.[@CIT0043] Although they were reported to play an important role in the metastasis of seminoma by activating MAP kinase and PI3K pathways, they have a limited role in tumor survival and proliferation.[@CIT0044] In the present study, we found that high expression levels of *CCR5* and *CXCR4* were associated with poor prognosis for seminoma patients. Maybe they are potential diagnostic biomaker or predictor for prognosis when more studies confirm their values.

Analysis of the four modules selected from the PPI network in the present study suggested that the Jak--STAT signaling pathway, chemokine signaling pathway, endocytosis, and cytokine--cytokine receptor interactions may be associated with the occurrence of seminoma. The Jak--STAT pathway is an evolutionarily conserved signaling cascade which mediates the response to cytokines and growth factors. Cellular responses to the activation of this pathway include differentiation, proliferation, migration, apoptosis, and cell survival. Moreover, Jak--STAT signaling is integral to homeostatic and developmental processes such as hematopoiesis, immune development, stem cell maintenance, and organismal growth,[@CIT0045] while its activation by dysregulated chemokines induces the occurrence and growth of cancer. Palagani et al reported that inhibiting the Jak--STAT pathway might prevent pancreatic cancer progression,[@CIT0046] and Li et al showed that its inhibition would promote the antiproliferative effect of methotrexate in small cell lung cancer.[@CIT0047] However, the relationship between seminoma and the Jak--STAT pathway requires further investigation. Maybe the Jak--STAT pathway is a promising candidate signaling pathway which affects the tumorigenesis of seminoma.

In conclusion, we used bioinformatics analysis of DEGs to identify key genes and pathways that are closely associated with the occurrence of seminoma. Our work identified several potential targets for biomarkers and for understanding underlying molecular mechanisms. However, further study is required to determine the functions of these candidates.
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TCGT, testicular germ cell tumors; AJCC, American Joint Committee on Cancer; DEGs, differentially expressed genes; GO, Gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; STRING, Search Tool for the Retrieval of Interacting Genes; PPI, protein--protein interaction; MCODE, Molecular Complex Detection; GEO, Gene Expression Omnibus; BP, biological processes; MF, molecular functions; CC, cellular component; DAVID, Database for Annotation, Visualization and Integrated Discovery; IL 6, interleukin 6; VEGFA, vascular endothelial growth factor A; CCR5, C-C motif chemokine receptor 5; CXCR4, C-X-C motif chemokine receptor 4; Jak--STAT, the Janus kinase-signal transducers and activators of transcription signaling pathway.
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